Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt

EU orphan designation number: EU/3/09/622   
Active ingredient: N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt
Indication: Treatment of acute myeloid leukaemia
Sponsor: Ambit Europe Limited
c/o Nortons, Highlands House, Basingstoke Road, Spencers Wood, Reading RG7 1NT, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/03/2009 Centralised Orphan - Designation EMEA/OD/105/08 (2009)2203 of 23/03/2009